<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87537</article-id><article-id pub-id-type="doi">10.7554/eLife.87537</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-309864"><name><surname>Basiri</surname><given-names>Mohsen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9592-4059</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310408"><name><surname>Ghaffari</surname><given-names>Mohammad E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278316"><name><surname>Ruan</surname><given-names>Jiapeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310409"><name><surname>Murugesan</surname><given-names>Vagishwari</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310410"><name><surname>Kleytman</surname><given-names>Nathaniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278309"><name><surname>Belinsky</surname><given-names>Glenn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310411"><name><surname>Akhavan</surname><given-names>Amir</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310412"><name><surname>Lischuk</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-310413"><name><surname>Guo</surname><given-names>Lilu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278321"><name><surname>Klinger</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-262226"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3447-6421</contrib-id><email>pramod.mistry@yale.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Internal Medicine, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ptbrd12</institution-id><institution>Department of ENT, Head and Neck Surgery, Guilan University of Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Rasht</named-content></addr-line><country>Islamic Republic of Iran</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Department of Rheumatology, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fzmm222</institution-id><institution>Department of Computer and Information Science, University of Massachusetts Dartmouth</institution></institution-wrap><addr-line><named-content content-type="city">Dartmout</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Radiology and Biomedical Imaging, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05g916f28</institution-id><institution>Translational Sciences, Sanofi</institution></institution-wrap><addr-line><named-content content-type="city">Framingham</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e87537</elocation-id><history><date date-type="received" iso-8601-date="2023-03-08"><day>08</day><month>03</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-05-22"><day>22</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2023-03-27"><day>27</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.21.23287476"/></event></pub-history><permissions><copyright-statement>© 2023, Basiri et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Basiri et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-87537-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>A salutary effect of treatments for Gaucher disease (GD) has been a reduction in the incidence of avascular osteonecrosis (AVN). However, there are reports of AVN in patients receiving enzyme replacement therapy (ERT) , and it is not known whether it is related to individual treatments, <italic>GBA</italic> genotypes, phenotypes, biomarkers of residual disease activity, or anti-drug antibodies. Prompted by development of AVN in several patients receiving ERT, we aimed to delineate the determinants of AVN in patients receiving ERT or eliglustat substrate reduction therapy (SRT) during 20 years in a tertiary referral center.</p></sec><sec id="abs2"><title>Methods:</title><p>Longitudinal follow-ups of 155 GD patients between 2001 and 2021 were analyzed for episodes of AVN on therapy, type of therapy, <italic>GBA1</italic> genotype, spleen status, biomarkers, and other disease indicators. We applied mixed-effects logistic model to delineate the independent correlates of AVN while receiving treatment.</p></sec><sec id="abs3"><title>Results:</title><p>The patients received cumulative 1382 years of treatment. There were 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. Heteroallelic p.Asn409Ser GD1 patients were 10 times (95% CI, 1.5–67.2) more likely than p.Asn409Ser homozygous patients to develop osteonecrosis during treatment. History of AVN prior to treatment initiation was associated with 4.8-fold increased risk of AVN on treatment (95% CI, 1.5–15.2). The risk of AVN among patients receiving velaglucerase ERT was 4.68 times higher compared to patients receiving imiglucerase ERT (95% CI, 1.67–13). No patient receiving eliglustat SRT suffered AVN. There was a significant correlation between GlcSph levels and AVN. Together, these biomarkers reliably predicted risk of AVN during therapy (ROC AUC 0.894, p&lt;0.001).</p></sec><sec id="abs4"><title>Conclusions:</title><p>There is a low, but significant risk of AVN in GD in the era of ERT/SRT. We found that increased risk of AVN was related to <italic>GBA</italic> genotype, history of AVN prior to treatment initiation, residual serum GlcSph level, and the type of ERT. No patient receiving SRT developed AVN. These findings exemplify a new approach to biomarker applications in a rare inborn error of metabolism to evaluate clinical outcomes in comprehensively followed patients and will aid identification of GD patients at higher risk of AVN who will benefit from closer monitoring and treatment optimization.</p></sec><sec id="abs5"><title>Funding:</title><p>LSD Training Fellowship from Sanofi to MB.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Gaucher disease</kwd><kwd>avascular osteonecrosis</kwd><kwd>lysosomal disease</kwd><kwd>GBA1</kwd><kwd>glucosylsphingosine</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013995</institution-id><institution>Sanofi Genzyme</institution></institution-wrap></funding-source><award-id>LSD Training Fellowship from Sanofi to MB</award-id><principal-award-recipient><name><surname>Basiri</surname><given-names>Mohsen</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Enhancing the management of Gaucher disease patients through multidimensional risk assessment serves as a roadmap towards personalized medicine in the context of a rare disease.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In Gaucher disease (GD), biallelic mutations in <italic>GBA1</italic> result in defective lysosomal glucocerebrosidase and the cellular accumulation of glucosylceramide (GlcCer) and its downstream metabolite, glucosylsphingosine (GlcSph) (<xref ref-type="bibr" rid="bib27">Mistry et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">van Dussen et al., 2014</xref>). These lipids accumulate classically in tissue macrophages and trigger a cascade of myeloid cell activation and chronic metabolic inflammation (<xref ref-type="bibr" rid="bib33">Orvisky et al., 2002</xref>; <xref ref-type="bibr" rid="bib36">Rigante et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Nair et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Nair et al., 2016</xref>).</p><p>Classical disease manifestations of GD include hepatosplenomegaly, cytopenia, and complex skeletal disease involving marrow infiltration, bone pain, osteopenia, fragility fractures, and recurrent avascular osteonecrosis (AVN) (<xref ref-type="bibr" rid="bib18">Hughes et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Grabowski et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Yeh et al., 2009</xref>). In the neuronopathic forms of the disease (GD type 2 and type 3), there is additionally childhood onset of neurodegeneration, spinal deformity, pectus carinatum, and pulmonary involvement. Remarkably, severely disabling skeletal manifestations, would a priori, will be expected to be associated with commensurate severe involvement of other disease compartment, but no such relationship can be discerned (<xref ref-type="bibr" rid="bib21">Khan et al., 2012</xref>). In a large study from the International Gaucher Registry (ICGG, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov</ext-link>: NCT00358943), occurrence of AVN did not correlate with severity of hepatosplenomegaly, genotype, thrombocytopenia, or extent of elevation of the disease biomarker, chitotriosidase. Only low hemoglobin and previous splenectomy were correlated with risk of AVN (<xref ref-type="bibr" rid="bib21">Khan et al., 2012</xref>). Therefore, clinicians and patients must remain vigilant of risk of AVN whether or not receiving treatment. Fortunately, there has been a reduction in the incidence of AVN since enzyme replacement therapy (ERT) with macrophage mannose receptor (MMR)-targeted imiglucerase became the standard of care in 1990s (<xref ref-type="bibr" rid="bib25">Mistry et al., 2009b</xref>). The incidence of osteonecrosis in untreated GD patients was reported to be 22.8 per 1000 person years (95% CI, 20.2–25.7) of follow-up. In small single center studies, AVN was reported in as many as half of GD patients (<xref ref-type="bibr" rid="bib12">Desnick et al., 1981</xref>; <xref ref-type="bibr" rid="bib9">Deegan et al., 2011</xref>). The introduction of ERT in the 1990s led to reduction in the incidence of AVN to 13.8 per 1000 years of follow-up. Studies have also shown striking reduction in reports of bone pain and bone crisis in the era of therapeutics (<xref ref-type="bibr" rid="bib41">van Dussen et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Mistry et al., 2017</xref>). Since 2010, two other MMR-targeted ERTs have become available: velaglucerase and taliglucerase (<xref ref-type="bibr" rid="bib6">Cox, 2013</xref>; <xref ref-type="bibr" rid="bib44">Zimran et al., 2013</xref>; <xref ref-type="bibr" rid="bib16">Gonzalez et al., 2013</xref>). Specific impact of newer ERTs on risk of AVN is not known. A recent introduction to first-line therapies for GD1 includes substrate reduction therapy (SRT), using eliglustat, a potent inhibitor of GlcCer synthase. In the extensive clinical trial program spanning more than 10 years, only few episodes of AVN were reported (<xref ref-type="bibr" rid="bib7">Cox et al., 2023</xref>). In the placebo-controlled ENGAGE trial, there was only one case of AVN, which occurred in a patient receiving placebo (<xref ref-type="bibr" rid="bib29">Mistry et al., 2021</xref>).</p><p>Despite the success of ERT in reducing the risk of AVN, there are occasional reports of AVN occurring in patients receiving ERT (<xref ref-type="bibr" rid="bib15">Goker-Alpan, 2011</xref>; <xref ref-type="bibr" rid="bib35">Potnis et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">de Fost et al., 2008</xref>). Therefore, it becomes important to understand whether there are identifiable risk factors for AVN, despite receiving GD-specific therapy. Knowledge of such factors will guide physicians in more comprehensive monitoring of patients beyond hematological and visceral disease as well as potentially advance understanding of underlying mechanisms. Prompted by AVN occurring in two pediatric patients despite ERT, we conducted an analysis of longitudinally followed patients at our tertiary national referral center to identify risk factors for AVN among patients receiving GD-specific therapy. We found patients with compound heterozygous p.Asn409Ser/other genotype, compared to p.Asn409Ser homozygous genotype, were at higher risk of AVN. Other risk factors included history of prior AVN before treatment initiation, type of ERT, and serum level of GlcSph, a validated biomarker of GD. GlcSph is downstream metabolite produced by deacylation of GlcCer via acid ceramidase. GlcSph is a relevant biomarker to study inflammatory manifestations of GD including AVN, as it is known to trigger immune activation and osteoblast dysfunction (<xref ref-type="bibr" rid="bib31">Nair et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Dekker et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Murugesan et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Saville et al., 2020</xref>).</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Patients</title><p>We conducted a retrospective study of 187 GD patients longitudinally followed from 2001 to December 2021 at our center. Our observational study is approved by Yale’s Human Investigation Committee. A total of 155 patients met the inclusion criteria including confirmed diagnosis of GD by enzymatic and molecular testing, known treatment status and date of initiation/switch (imiglucerase, velaglucerase, and eliglustat), known splenectomy status, previous history of AVN and longitudinal data of MRI volumetrics for liver and spleen, CBC, and biomarkers including GlcSph and chitotriosidase.</p><p>Diagnosis of GD was based on diminished levels (&lt;10% compared to controls) of acid β-glucosidase activity in peripheral blood leukocytes and full <italic>GBA1</italic> sequencing using a combination of pacBio sequencing, WES, and Sanger sequencing, as described previously (<xref ref-type="bibr" rid="bib14">Drelichman et al., 2021</xref>). Patients were followed every 1–2 years with standard of care evaluations, including MRI to assess organomegaly and marrow infiltration, and laboratory testing (<xref ref-type="bibr" rid="bib5">Charrow et al., 1998</xref>). Volumetric MRI of liver and spleen was converted to multiples of normal with normal liver volume: 2.5% of body weight and normal spleen volume: 0.2% body weight. Patients developing new bone pain were evaluated earlier. Serum samples were collected at each clinic visit to determine biomarker trends for GlcSph and chitotriosidase, as well as other indicators of disease activity.</p></sec><sec id="s2-2"><title>Surrogate disease biomarkers</title><p>Serum chitotriosidase activities were determined using a method described previously, with slight modifications (<xref ref-type="bibr" rid="bib39">Schoonhoven et al., 2007</xref>). Briefly, assay buffer was adjusted to pH 4.5, and the final concentration of 4- methylumbelliferyl-beta-D-<italic>N</italic>,<italic>N</italic>’,<italic>N</italic>”-triacetylchitotriose fluorogenic substrate was 10 µM. <italic>CHIT1</italic> genotyping was performed to normalize serum levels as described previously (<xref ref-type="bibr" rid="bib3">Boot et al., 1998</xref>). Serum GlcSph levels were measured via liquid chromatography coupled to tandem mass spectrometry (<xref ref-type="bibr" rid="bib30">Murugesan et al., 2016</xref>). Normal healthy control levels were ≤1 ng/ml.</p></sec><sec id="s2-3"><title>AVN episodes</title><p>Generally, episodes of AVN were associated with new bone pain or exacerbation of chronic bone pain that prompted new visits, earlier than regular 1–2 yearly follow-ups. Occasionally, we found new AVN on MRI scans and on closer questioning patients reported bone pain that they managed symptomatically.</p></sec><sec id="s2-4"><title>Statistical analysis</title><p>Frequency and percentage were used to describe qualitative data and mean, and standard deviation were used for quantitative data. Mixed-effects logistic regression was applied to analyze repeated-measure data during treatment. In this study, three mixed-effects models were fitted on the data: a logistic mixed-effects model with the response of AVN incidence and two linear mixed models with the responses of chitotriosidase and GlcSph to different therapies. A random intercept was chosen to account for the presence of different quantitative variables and the uniformity of sizes with different numbers for patients (<xref ref-type="bibr" rid="bib13">Detry and Ma, 2016</xref>). To compare the effect of each treatment on the changes of chitotriosidase and GlcSph, a linear mixed model with two-by-two Bonferroni comparisons was used. The structure of logistics mixed model was as follows:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi mathvariant="normal">x</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">z</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi mathvariant="normal">x</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="normal">z</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="normal">x</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi mathvariant="normal">z</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msubsup><mml:mi mathvariant="normal">u</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where Y<sub>i</sub> is a binary variable describing the outcome of case i (0 or 1), β is a fixed parameter vector, x<sub>i</sub> is a covariate vector for fixed effects, u is a vector of random variables from probability distributions, and z<sub>i</sub> is a covariate vector for random effects. u represents unmeasured covariates as a way of modeling heterogeneity and correlated data.</p><p>In the model used in our study, the response variable is incidence of AVN during treatment (yes/no). For fixed effects, the covariates included type of treatment (imiglucerase, velaglucerase, and eliglustat), previous history of AVN (occurrence and non-occurrence), sex, <italic>GBA1</italic> genotype, spleen status (intact spleen with volumetric measurement or splenectomized), and GlcSph, chitotriosidase, hemoglobin, platelet count, spleen volume, liver volume. The random effect was intercept. Several variance-covariance structures were examined for obtaining the best fit. To make this selection, Akaike’s information criteria was used for the least value. Autoregressive of Order 1 (Ar (1)) was chosen based on this criterion. All statistical analyses were performed with SPSS version 28 (SPSS Inc, Chicago, IL, USA). A p-value &lt;0.05 was considered statistically significant. MedCalc version 20.026 was used for ROC curve analysis and graphs were plotted by GraphPad Prism version 9.3.1.</p></sec><sec id="s2-5"><title>Illustrative cases: the importance of awareness of AVN in pediatric patients</title><p>Two illustrative cases underscore the premise for our study. Patient 1 was born in in 2006–2010, had presented at pre-school age with history of chronic epistaxis and easy bruising, and found to have cytopenia and splenomegaly. The proband was diagnosed with GD1, <italic>GBA1</italic> genotype p.Asn409Ser/c.217delC mutations. Liver and spleen volumes were 1.68 and 10.68 multiples of normal respectively. The patient was commenced velaglucerase ERT at dose 60 U/kg/2 weeks. The patient developed infusion-associated reactions (IARs) initially controlled with premedication but became refractory by 24th infusion and was switched to taliglucerase ERT which also caused IARs. Further switch back to velaglucerase caused recurrent IARs. Hematological parameters began to decline and at age 6–10 and developed severe pain in femur concerning for AVN. Plain radiology was normal. Symptoms progressed, and patient was confined to the wheelchair. MRIs revealed diffuse bone marrow signal abnormality throughout the femur consistent with osteonecrosis in left femur (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Few months later, the patient developed AVN in right femur (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Patient was evaluated at our center 1 year later. The patient appeared chronically ill and in pain, was in wheelchair, and had limited ability to weight-bear. Further studies revealed that patient had developed pan-neutralizing antibodies to all enzyme preparations (velaglucerase, imiglucerase, taliglucerase) after starting velaglucerase ERT. Due to high risk of extension of primary AVN in the femora and recurrent AVN at other sites, we secured approval from our IRB for treatment with eliglustat via Emergency Use Protocol. During past 6 years on eliglustat, there have been no further bone crises, Hb increased from 10.6 to 13.6, and platelets from 107 to 184. Concomitantly, serum GlcSph was reduced from 644 ng/ml to 101 ng/ml.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>T2 weighted and STIR MR images of the patient 1 described in section Illustrative cases: the importance of awareness of AVN in pediatric patients.</title><p>(<bold>A</bold>) T2 weighted MR image of the femurs, showing diffuse bone marrow signal abnormality throughout the left femur with associated periostitis and subperiosteal fluid collection. (<bold>B</bold>) STIR MR image of the pelvis of the same patient 1 year after. (A) showing an expanding lesion of the greater trochanter, superiorly displacing fragments of bone and collapsed right hip joint.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87537-fig1-v2.tif"/></fig><sec id="s2-5-1"><title>Patient 2</title><p>The proband who was in good state of health, started to suffer from left femur pain during school age requiring multiple ER admissions. Initial diagnosis included leg sprain, growing pains, Lyme arthritis, and then osteomyelitis based on MRI findings. Despite antibiotics, femur pain persisted and pathology of debridement for presumed osteomyelitis was positive for Gaucher cells. <italic>GBA1</italic> genotype was p.Asn409Ser/p.Leu483Pro mutations. The proband was started on velaglucerase ERT but few months later, the patient had recurrent AVN in left femur. The patient was switched to imiglucerase and has been remained free of AVN and hematological, visceral, and biomarkers indicators show stable GD activity. More recently after the patient turned young adult, was switched to eliglustat SRT and continued to do well.</p></sec></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Patient demographics and AVN on treatment</title><p>The demographics of patients in the study are shown in <xref ref-type="table" rid="table1">Table 1</xref>. The cohort comprises 79 (50.3%) male individuals. Of the 155 patients studied, 42 (27.1%) had history of osteonecrosis prior to treatment initiation and 32 patients (20.6%) had undergone prior splenectomy.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographic characteristics of the patients in this study.</title><p>Among 187 Gaucher disease patients followed longitudinally from 2001 to December 2021, a total of 155 patients met the inclusion criteria (explained in section Patients). Qualitative data were described by frequency and percentage and mean, and standard deviation (SD) were used for quantitative data. <italic>GBA1</italic>: glucosylceramidase beta 1, WBC: white blood cell, HgB: hemoglobin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top">All(N=155)</th><th align="left" valign="top"/><th align="left" valign="top">All(N=155)</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>Age at first visit (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top"><bold>Number of visits</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">33.81 (18.74)</td><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">6.1 (4.17)</td></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">34 (2, 85)</td><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">5.0 (1, 25)</td></tr><tr><td align="left" valign="top"><bold>Gender</bold></td><td align="left" valign="top"/><td align="left" valign="top"><bold>Duration of follow-up (year</bold>)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Female:Male</td><td align="char" char="." valign="top">77 (49.7 %):78 (50.3%)</td><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">14.0 (12)</td></tr><tr><td align="left" valign="top"><bold>Age at first symptoms (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">12(1,20)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">20.02 (16.1)</td><td align="left" valign="top"><bold>Osteonecrosis while untreated</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">17.0 (5, 65)</td><td align="left" valign="top">Yes</td><td align="char" char="." valign="top">42 (27.1%)</td></tr><tr><td align="left" valign="top"><bold>Age at diagnosis (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">No</td><td align="char" char="." valign="top">113 (72.9.%)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">23.2 (17.3)</td><td align="left" valign="top"><bold>Spleen status</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">22.0 (5, 67)</td><td align="left" valign="top">Intact spleen</td><td align="char" char="." valign="top">123 (79.4%)</td></tr><tr><td align="left" valign="top"><bold>Gap to diagnosis in men (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">Splenectomized</td><td align="char" char="." valign="top">32 (20.6%)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">11.2 (12.6)</td><td align="left" valign="top"><bold>Type of treatment (year</bold>)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">5.5 (0, 57)</td><td align="left" valign="top">Imiglucerase</td><td align="char" char="." valign="top">834 (60.3%)</td></tr><tr><td align="left" valign="top"><bold>Gap to diagnosis in women (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">Eliglustat</td><td align="char" char="." valign="top">238 (17.2%)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">10.3 (11.2)</td><td align="left" valign="top">Velaglucerase</td><td align="char" char="." valign="top">310 (22.4%)</td></tr><tr><td align="left" valign="top">median (min, max)</td><td align="char" char="." valign="top">7 (0, 40)</td><td align="left" valign="top"><bold>Clinical variables: mean (SD</bold>)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><bold>Age at starting treatment (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">Hermann score</td><td align="char" char="." valign="top">2.84 (1.6)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">33 (18)</td><td align="left" valign="top">Severity score index</td><td align="char" char="." valign="top">7.62 (3.8)</td></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">29 (2, 85)</td><td align="left" valign="top">Chitotriosidase (nmol/hr/ml)</td><td align="char" char="." valign="top">1106.15 (2801.3)</td></tr><tr><td align="left" valign="top"><bold>Gap to start treatment (year</bold>)</td><td align="left" valign="top"/><td align="left" valign="top">Glucosylsphingosine (ng/ml)</td><td align="char" char="." valign="top">58.12 (22.5)</td></tr><tr><td align="left" valign="top">Mean (SD)</td><td align="char" char="." valign="top">10.5 (11)</td><td align="left" valign="top">Liver volume in cc</td><td align="char" char="." valign="top">1676.40 (186.4)</td></tr><tr><td align="left" valign="top">Median (min, max)</td><td align="char" char="." valign="top">9 (0, 57)</td><td align="left" valign="top">Liver multiples of normal</td><td align="char" char="." valign="top">0.94 (0.24)</td></tr><tr><td align="left" valign="top"><bold><italic>GBA1</italic> genotype</bold></td><td align="left" valign="top"/><td align="left" valign="top">Spleen volume in cc</td><td align="char" char="." valign="top">480.9 (146.8)</td></tr><tr><td align="left" valign="top">p.Asn409Ser/p.Asn409Ser</td><td align="char" char="." valign="top">78 (51%)</td><td align="left" valign="top">Spleen multiples of normal</td><td align="char" char="." valign="top">3.47 (2.95)</td></tr><tr><td align="left" valign="top">p.Asn409Ser/p.Leu483Pro</td><td align="char" char="." valign="top">20 (13.1%)</td><td align="left" valign="top">WBC ×10<sup>3</sup> u/l</td><td align="char" char="." valign="top">6.46 (3.48)</td></tr><tr><td align="left" valign="top">p.Asn409Ser/84GG</td><td align="char" char="." valign="top">14 (9.2%)</td><td align="left" valign="top">Hgb in g/dl</td><td align="char" char="." valign="top">13.92 (1.6)</td></tr><tr><td align="left" valign="top">p.Asn409Ser/IVS2+1</td><td align="char" char="." valign="top">6 (3.9%)</td><td align="left" valign="top">Platelets ×10<sup>3</sup> u/l</td><td align="char" char="." valign="top">200.6 (87.1)</td></tr><tr><td align="left" valign="top">p.Asn409Ser/other</td><td align="char" char="." valign="top">27 (17.6%)</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Other/other</td><td align="char" char="." valign="top">8 (5.2%)</td><td align="left" valign="top"/><td align="left" valign="top"/></tr></tbody></table></table-wrap><p>During 20 years’ span of this study, there were 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. In aggregate, the patients received 1382 cumulative years of treatment. By treatment type, total treatment years for imiglucerase ERT was 834 years and a total of six episodes of AVN occurred on imiglucerase ERT, that is 0.72 AVN per 100 years imiglucerase. Patients received cumulative 310 years velaglucerase ERT and there were 10 episodes of AVN, that is 3.2 AVN per 100 years of velaglucerase ERT. Total treatment years for eliglustat SRT was 238 years and so far, there have been no episodes of AVN among patients receiving eliglustat SRT. The demographics of these 14 patients shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Demographics and clinical features of patients with osteonecrosis on treatment at the proximity to avascular osteonecrosis (AVN) occurrence.</title><p>Modes of presentation of AVN shown as ‘painful’ indicating new onset of bone pain prompting early evaluation and ‘silent’ discovered on routine annual MRI and in retrospect, further history indicated patients had exacerbation of chronic pain that they treated symptomatically. * age range: C (child: age &lt;18), YA (young adult: age 18–40), MA (middle-aged adult: age 40–60), OA (older adult: age &gt;60). Shown are GBA1 genotype, age at AVN, type of treatment, history of AVN prior to treatment, serum biomarkers, liver/spleen volumes, and interval between diagnosis and initiation of treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2">AVNoccurrence</th><th align="left" valign="bottom">Gender</th><th align="left" valign="bottom">Genotype in <italic>GBA1</italic></th><th align="left" valign="bottom">Age at AVN (category)*</th><th align="left" valign="bottom">Type of ERT</th><th align="left" valign="bottom">History of AVN</th><th align="left" valign="bottom">Age at Diagnosis (category)*</th><th align="left" valign="bottom">Gap to diagnosis (years)</th><th align="left" valign="bottom">Age at ERT initiation (category)*</th><th align="left" valign="bottom">Gap to ERT initiation(year)</th><th align="left" valign="bottom">Type of AVN</th><th align="left" valign="bottom">Location</th><th align="left" valign="bottom">Hemoglobin(gm/dl)</th><th align="left" valign="bottom">Platelet(×1000 u/l)</th><th align="left" valign="bottom">Liver multiples of normal</th><th align="left" valign="bottom">Spleen multiples of normal</th><th align="left" valign="bottom">Chitotriosidase (nmol/hr/ml)</th><th align="left" valign="bottom">GlcSph(ng/ml)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom">Patient no. 1</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Asn409Ser<break/>/84GG</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom">Silent</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">17.1</td><td align="char" char="." valign="bottom">111</td><td align="char" char="." valign="bottom">0.89</td><td align="char" char="." valign="bottom">5.2</td><td align="char" char="." valign="bottom">389.8</td><td align="char" char="." valign="bottom">93.7</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">Patient no. 2</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Ile442Thr</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">15.6</td><td align="char" char="." valign="bottom">252</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">1.8</td><td align="char" char="." valign="bottom">743.5</td><td align="char" char="." valign="bottom">158.3</td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">Patient no. 3</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Leu483Pro<break/>/p.Asn501Lys</td><td align="left" valign="bottom">OA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">OA</td><td align="char" char="." valign="bottom">25</td><td align="left" valign="bottom">Silent</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">14.0</td><td align="char" char="." valign="bottom">313</td><td align="char" char="." valign="bottom">0.80</td><td align="left" valign="bottom">Splenectemized</td><td align="char" char="." valign="bottom">332.9</td><td align="char" char="." valign="bottom">69.2</td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom">Patient no. 4</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Leu483Pro</td><td align="left" valign="bottom">YA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">0.2</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">0.1</td><td align="left" valign="bottom">Silent</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">13.3</td><td align="char" char="." valign="bottom">244</td><td align="char" char="." valign="bottom">0.96</td><td align="char" char="." valign="bottom">1.56</td><td align="char" char="." valign="bottom">1962</td><td align="char" char="." valign="bottom">89.8</td></tr><tr><td align="char" char="." valign="bottom"><bold>5</bold></td><td align="left" valign="bottom">Patient no. 5</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Leu483Pro</td><td align="left" valign="bottom">C</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">0.1</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">13.4</td><td align="char" char="." valign="bottom">212</td><td align="char" char="." valign="bottom">1.12</td><td align="char" char="." valign="bottom">3.1</td><td align="char" char="." valign="bottom">731.4</td><td align="char" char="." valign="bottom">143.5</td></tr><tr><td align="char" char="." valign="bottom"><bold>6</bold></td><td align="left" valign="bottom">Patient no. 6</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Asp166Glu</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">0.4</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Shoulder</td><td align="char" char="." valign="bottom">15.8</td><td align="char" char="." valign="bottom">90</td><td align="char" char="." valign="bottom">1.82</td><td align="char" char="." valign="bottom">9.1</td><td align="char" char="." valign="bottom">3.4</td><td align="char" char="." valign="bottom">248.2</td></tr><tr><td align="char" char="." valign="bottom"><bold>7</bold></td><td align="left" valign="bottom">Patient no. 7</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Arg502Ser</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">11.6</td><td align="char" char="." valign="bottom">238</td><td align="char" char="." valign="bottom">1.49</td><td align="char" char="." valign="bottom">5.8</td><td align="char" char="." valign="bottom">731</td><td align="char" char="." valign="bottom">85</td></tr><tr><td align="char" char="." valign="bottom"><bold>8</bold></td><td align="left" valign="bottom">Patient no. 7</td><td align="left" valign="bottom" colspan="2"> Second episode</td><td align="left" valign="bottom">OA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Hip</td><td align="char" char="." valign="bottom">12.5</td><td align="char" char="." valign="bottom">235</td><td align="char" char="." valign="bottom">1.41</td><td align="char" char="." valign="bottom">5.4</td><td align="char" char="." valign="bottom">733.6</td><td align="char" char="." valign="bottom">145.7</td></tr><tr><td align="char" char="." valign="bottom"><bold>9</bold></td><td align="left" valign="bottom">Patient no. 8</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/c.217delC</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">0.1</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">11.0</td><td align="char" char="." valign="bottom">222</td><td align="char" char="." valign="bottom">0.8</td><td align="left" valign="bottom">Splenectemized</td><td align="char" char="." valign="bottom">523.4</td><td align="char" char="." valign="bottom">61.9</td></tr><tr><td align="char" char="." valign="bottom"><bold>10</bold></td><td align="left" valign="bottom">Patient no. 8</td><td align="left" valign="bottom" colspan="2"> Second episode</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">10.1</td><td align="char" char="." valign="bottom">322</td><td align="char" char="." valign="bottom">0.75</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">623.9</td><td align="char" char="." valign="bottom">77.7</td></tr><tr><td align="char" char="." valign="bottom"><bold>11</bold></td><td align="left" valign="bottom">Patient no. 9</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/IVS2+1</td><td align="left" valign="bottom">OA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Hip</td><td align="char" char="." valign="bottom">13.3</td><td align="char" char="." valign="bottom">474</td><td align="char" char="." valign="bottom">0.73</td><td align="left" valign="bottom">Splenectemized</td><td align="char" char="." valign="bottom">563.6</td><td align="char" char="." valign="bottom">128.4</td></tr><tr><td align="char" char="." valign="bottom"><bold>12</bold></td><td align="left" valign="bottom">Patient no. 10</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Leu483Pro</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Imiglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Ankle</td><td align="char" char="." valign="bottom">16.7</td><td align="char" char="." valign="bottom">299</td><td align="char" char="." valign="bottom">0.88</td><td align="left" valign="bottom">Splenectemized</td><td align="char" char="." valign="bottom">3123.4</td><td align="char" char="." valign="bottom">223.8</td></tr><tr><td align="char" char="." valign="bottom"><bold>13</bold></td><td align="left" valign="bottom">Patient no. 11</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Arg463Cys<break/>/p.255Tyr</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">MA</td><td align="char" char="." valign="bottom">5</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Hip</td><td align="char" char="." valign="bottom">14.5</td><td align="char" char="." valign="bottom">253</td><td align="char" char="." valign="bottom">0.91</td><td align="char" char="." valign="bottom">1.6</td><td align="char" char="." valign="bottom">1852.5</td><td align="char" char="." valign="bottom">86.3</td></tr><tr><td align="char" char="." valign="bottom"><bold>14</bold></td><td align="left" valign="bottom">Patient no. 12</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/c.217delC</td><td align="left" valign="bottom">C</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Femur</td><td align="char" char="." valign="bottom">11.5</td><td align="char" char="." valign="bottom">124</td><td align="char" char="." valign="bottom">1.38</td><td align="char" char="." valign="bottom">7.7</td><td align="char" char="." valign="bottom">4134.6</td><td align="char" char="." valign="bottom">318.6</td></tr><tr><td align="char" char="." valign="bottom"><bold>15</bold></td><td align="left" valign="bottom">Patient no. 13</td><td align="left" valign="bottom">F</td><td align="left" valign="bottom">p.Asn409Ser<break/>/p.Asn409Ser</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Hand</td><td align="char" char="." valign="bottom">13.6</td><td align="char" char="." valign="bottom">189</td><td align="char" char="." valign="bottom">0.83</td><td align="char" char="." valign="bottom">1.5</td><td align="char" char="." valign="bottom">26.2</td><td align="char" char="." valign="bottom">21.9</td></tr><tr><td align="char" char="." valign="bottom"><bold>16</bold></td><td align="left" valign="bottom">Patient no. 14</td><td align="left" valign="bottom">M</td><td align="left" valign="bottom">p.Asn409Ser<break/>/84GG</td><td align="left" valign="bottom">MA</td><td align="left" valign="bottom">Velaglucerase</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">C</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">YA</td><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom">Painful</td><td align="left" valign="bottom">Navicular</td><td align="char" char="." valign="bottom">13.7</td><td align="char" char="." valign="bottom">147</td><td align="char" char="." valign="bottom">1.12</td><td align="char" char="." valign="bottom">4.15</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">210.3</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><title>Delineating the determinants of AVN on treatment</title><p>Mixed-effects logistic regression was applied for analyzing repeated-measure data during treatment to decipher risk factors for developing AVN on treatment (<xref ref-type="table" rid="table3">Table 3</xref>). Heteroallelic p.Asn409Ser GD patients were 10 times (95% CI, 1.5–67.2, p=0.003) more likely than p.Asn409Ser homozygous patients to develop osteonecrosis during treatment. History of AVN prior to treatment initiation increased the risk of AVN by 4.8-fold while receiving a specific GD treatment (95% CI, 1.5–15.24, p=0.008). The risk of AVN among patients who had received velaglucerase ERT was 4.7 times higher compared to patients receiving imiglucerase ERT (95% CI, 1.67–13.07, p=0.003). No patient receiving eliglustat SRT suffered AVN. There was a significant correlation between residual GlcSph levels and AVN (95% CI, 1.004–1.02, p=0.004). For every 1 ng/ml increase in the level of GlcSph, there was estimated 1.2% increase in the risk of developing osteonecrosis during treatment. Level of serum GlcSph at first and second episode of AVN in two patients further underscores the role of GlcSph for risk prediction. As shown in <xref ref-type="table" rid="table2">Table 2</xref>, patient # 7 had developed first AVN when GlcSph was 85 ng/ml. The second episode of AVN when the serum level of GlcSph was 145.7 ng/ml. Similarly, patient # 8 developed AVN while the serum level of GlcSph was 61.9 ng/ml. The second episode of AVN when the serum level of GlcSph was 77.7 ng/ml.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Output of mixed-effects modeling.</title><p>To determine the clinical context in which avascular osteonecrosis (AVN) occurs in Gaucher disease (GD) patients while receiving enzyme replacement therapy (ERT). Eliglustat substrate reduction therapy (SRT) was not included in the model as there were no episodes of AVN on patients receiving this therapy at the time of analysis. A random intercept was chosen to account for the presence of different quantitative variables and the uniformity of sizes with different numbers for patients. (Further explanation in sections Statistical analysis and Delineating the determinants of AVN on treatment.)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="11">Fixed coefficients</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"> Model term<xref ref-type="table-fn" rid="table3fn2">*</xref></td><td align="left" valign="bottom" rowspan="2">Coefficient</td><td align="left" valign="bottom" rowspan="2">Std. error</td><td align="left" valign="bottom" rowspan="2">t</td><td align="left" valign="bottom" rowspan="2">Sig.</td><td align="left" valign="bottom" colspan="2">95% Confidence interval</td><td align="left" valign="bottom" rowspan="2">Exp(coefficient)</td><td align="left" valign="bottom" colspan="2">95% Confidence Interval for Exp(coefficient)</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Lower</td><td align="left" valign="bottom">Upper</td><td align="left" valign="bottom">Lower</td><td align="left" valign="bottom">Upper</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Intercept</td><td align="char" char="." valign="bottom">–9.392</td><td align="char" char="." valign="bottom">1.2846</td><td align="char" char="." valign="bottom">–7.311</td><td align="char" char="." valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">–11.913</td><td align="char" char="." valign="bottom">–6.872</td><td align="char" char="hyphen" valign="bottom">8.337E-5</td><td align="char" char="hyphen" valign="bottom">6.705E-6</td><td align="char" char="." valign="bottom">0.001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Rx: velaglucerase</td><td align="char" char="." valign="bottom">1.543</td><td align="char" char="." valign="bottom">0.5235</td><td align="char" char="." valign="bottom">2.948</td><td align="char" char="." valign="bottom">0.003</td><td align="char" char="." valign="bottom">0.516</td><td align="char" char="." valign="bottom">2.570</td><td align="char" char="." valign="bottom">4.680</td><td align="char" char="." valign="bottom">1.676</td><td align="char" char="." valign="bottom">13.071</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Rx: imiglucerase</td><td align="char" char="." valign="bottom">0<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> AVN pre-Rx: Yes</td><td align="char" char="." valign="bottom">1.568</td><td align="char" char="." valign="bottom">0.5894</td><td align="char" char="." valign="bottom">2.659</td><td align="char" char="." valign="bottom">0.008</td><td align="char" char="." valign="bottom">0.411</td><td align="char" char="." valign="bottom">2.724</td><td align="char" char="." valign="bottom">4.795</td><td align="char" char="." valign="bottom">1.508</td><td align="char" char="." valign="bottom">15.243</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> AVN pre-Rx: No</td><td align="char" char="." valign="bottom">0<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Gender: female</td><td align="char" char="." valign="bottom">0.859</td><td align="char" char="." valign="bottom">0.5298</td><td align="char" char="." valign="bottom">1.620</td><td align="char" char="." valign="bottom">0.105</td><td align="char" char="." valign="bottom">–0.181</td><td align="char" char="." valign="bottom">1.898</td><td align="char" char="." valign="bottom">2.360</td><td align="char" char="." valign="bottom">0.834</td><td align="char" char="." valign="bottom">6.673</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Gender: male</td><td align="char" char="." valign="bottom">0<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Spleen status:<break/> Splenectomized</td><td align="char" char="." valign="bottom">0.754</td><td align="char" char="." valign="bottom">0.5851</td><td align="char" char="." valign="bottom">1.288</td><td align="char" char="." valign="bottom">0.198</td><td align="char" char="." valign="bottom">–0.394</td><td align="char" char="." valign="bottom">1.902</td><td align="char" char="." valign="bottom">2.125</td><td align="char" char="." valign="bottom">0.674</td><td align="char" char="." valign="bottom">6.697</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Spleen status: intact</td><td align="char" char="." valign="bottom">0<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Genotype: other/other</td><td align="char" char="." valign="bottom">1.903</td><td align="char" char="." valign="bottom">1.3717</td><td align="char" char="." valign="bottom">1.387</td><td align="char" char="." valign="bottom">0.166</td><td align="char" char="." valign="bottom">–0.789</td><td align="char" char="." valign="bottom">4.594</td><td align="char" char="." valign="bottom">6.705</td><td align="char" char="." valign="bottom">0.454</td><td align="char" char="." valign="bottom">98.919</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Genotype: p.Asn409Ser/other</td><td align="char" char="." valign="bottom">2.309</td><td align="char" char="." valign="bottom">0.9685</td><td align="char" char="." valign="bottom">2.384</td><td align="char" char="." valign="bottom">0.017</td><td align="char" char="." valign="bottom">0.409</td><td align="char" char="." valign="bottom">4.209</td><td align="char" char="." valign="bottom">10.063</td><td align="char" char="." valign="bottom">1.505</td><td align="char" char="." valign="bottom">67.297</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Genotype:<break/> p.Asn409Ser/p.Asn409Ser</td><td align="char" char="." valign="bottom">0<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="char" char="." valign="bottom">.</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Serum level of<break/>glucosylsphingosine<break/>(ng/ml)</td><td align="char" char="." valign="bottom">0.012</td><td align="char" char="." valign="bottom">0.0040</td><td align="char" char="." valign="bottom">2.880</td><td align="char" char="." valign="bottom">0.004</td><td align="char" char="." valign="bottom">0.004</td><td align="char" char="." valign="bottom">0.020</td><td align="char" char="." valign="bottom">1.012</td><td align="char" char="." valign="bottom">1.004</td><td align="char" char="." valign="bottom">1.020</td><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>Probability distribution: BinomialLink function: Logit.</p></fn><fn id="table3fn2"><label>*</label><p>Target: occurrence of AVN during treatment.</p></fn><fn id="table3fn3"><label>†</label><p>This coefficient is set to zero because it is redundant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Assessing the role of serum GlcSph levels for the risk of AVN</title><p>ROC curve analysis was done to estimate cut-offs for GlcSph levels to predict the risk of AVN in GD patients while receiving treatment. The ROC curve shows true positive rate (sensitivity) as a function of the false positive rate (100-specificity) for different cut-off points. We found the value of the area under the ROC curve at GlcSph serum level of 77.64 ng/ml to be 0.857 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), that is GlcSph level is a significant variable correlated with the incidence of AVN while receiving treatment.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Diagnostic accuracy of serum level of glucosylsphingosine (GlcSph) for diagnosis of avascular osteonecrosis (AVN) on treatment: ROC curve analysis was done to assess the diagnostic accuracy cut-offs for GlcSph levels to predict the risk of AVN in Gaucher disease (GD) patients while receiving treatment.</title><p>(<bold>A</bold>) We found the value of the area under the ROC curve at GlcSph serum level of 77.64 ng/ml to be 0.857. GlcSph level of 77.64 ng/ml has sensitivity of 81.2% (95% CI, 54.4–96%) and specificity of 82.8% (95% CI, 80.7–84.8%) for association with AVN in entire GD patients receiving treatment. (<bold>B</bold>) As shown here, clinical significance of GlcSph levels is enhanced by considering their context of use regarding other risk factors. In patients with at least one of delineated risk factors in our study, that is compound heterozygosity for p.Asn409Ser, history of AVN prior to treatment or velaglucerase ERT, sensitivity for GlcSph level at 77.64 ng/ml increases to 87.5%. (<bold>C</bold>) In patients who harbor at least two of delineated risk factors in this study, GlcSph level of 77.14 ng/ml has sensitivity of 92.9% and specificity of 78.8% to rule in the probability of AVN on ERT. (<bold>D</bold>) In patients with all three risk factors delineated in the study, GlcSph level of 71.8 ng/ml is 100% sensitive to support the probability of AVN with specificity of 82.4%.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87537-fig2-v2.tif"/></fig></sec><sec id="s3-4"><title>Effect of GD-specific therapies on biomarkers, Chitotriosidase and GlcSph</title><p>The three drugs used to treat GD showed differential response in reducing serum chitotriosidase activity. Velaglucerase appeared to be most effective in reducing chitotriosidase, followed by imiglucerase. Pairwise comparisons showed the mean chitotriosidase in patients receiving velaglucerase was significantly lower than eliglustat, however, no significant difference was observed between velaglucerase and imiglucerase (p&gt;0.999), (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect of different therapies on chitotriosidase and glucosylsphingosine (GlcSph).</title><p>To compare the effect of each treatment on the changes of chitotriosidase and GlcSph, a linear mixed model with two-by-two Bonferroni comparisons was used.</p><p>(<bold>A</bold>) Effects of three drugs on chitotriosidase (nmol/hr/ml): pairwise comparisons showed velaglucerase is most effective in reducing chitotriosidase, followed by imiglucerase, followed by eliglustat. (<bold>B</bold>) Effects of three drugs on GlcSph (ng/ml): three drugs were significantly different for effect on GlcSph reduction (p&lt;0.001). Eliglustat was the most effective in reducing serum GlcSph, followed by imiglucerase, followed by velaglucerase. Pairwise comparisons showed that the mean serum GlcSph in eliglustat-treated patients was significantly lower than the enzyme replacement therapies (ERTs). There was no significant difference in patients receiving velaglucerase vs imiglucerase (p=0.478).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-87537-fig3-v2.tif"/></fig><p>Next, we examined serum GlcSph biomarker, and we found the three drugs were significantly different for effect on GlcSph reduction (p&lt;0.001). Eliglustat was the most effective in reducing serum GlcSph, followed by imiglucerase, followed by velaglucerase. Pairwise comparisons showed that the mean serum GlcSph in eliglustat-treated patients was significantly lower than the ERTs. There was no significant difference in patients receiving velaglucerase vs imiglucerase (p=0.478). (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>AVN is one of the most devastating and life-altering manifestations of GD that results in chronic disability and need for orthopedic surgeries (<xref ref-type="bibr" rid="bib22">Marcucci et al., 2014</xref>). The underlying mechanism(s) of osteonecrosis in GD is not understood. Several mechanisms have been proposed, including disruption of microcirculation by lipid-laden Gaucher macrophages, abnormal red cell morphology leading to ischemia, and osteocyte death (<xref ref-type="bibr" rid="bib23">Mikosch and Hughes, 2010</xref>). Bone marrow cells in GD exhibit abnormal secretome and osteoblast dysfunction in GD has been linked with accumulating bioactive Gaucher lipid, GlcSph (<xref ref-type="bibr" rid="bib26">Mistry et al., 2010</xref>; <xref ref-type="bibr" rid="bib4">Campeau et al., 2009</xref>). There is also evidence of aberrant osteoclast-osteoblast coupling via reduced sphingosine-1-phosphate in GD (<xref ref-type="bibr" rid="bib37">Ryu et al., 2006</xref>; <xref ref-type="bibr" rid="bib20">Ishii et al., 2009</xref>). Another emerging player in bone cellular pathology of GD is the damage-associated molecular patterns released by necrotic osteocytes via macrophage-inducible C-type lectin (Mincle), which is known to induce osteoclastogenesis and bone loss (<xref ref-type="bibr" rid="bib1">Andreev et al., 2020</xref>). In patients with osteonecrosis, Mincle was highly expressed at skeletal sites of osteocyte death and correlated with strong osteoclastic activity (<xref ref-type="bibr" rid="bib1">Andreev et al., 2020</xref>). GlcCer is a ligand for Mincle, which underscores the complex bone marrow-bone microenvironment in GD and need for optimal therapeutic targeting to prevent disabling AVN.</p><p>While AVN occurred frequently in GD in the pre-ERT era (<xref ref-type="bibr" rid="bib28">Mistry et al., 2017</xref>), introduction of ERT since 1991 has reduced its incidence (<xref ref-type="bibr" rid="bib25">Mistry et al., 2009b</xref>; <xref ref-type="bibr" rid="bib24">Mistry et al., 2009a</xref>). However, there are occasional reports of AVN among GD patients receiving ERT (<xref ref-type="bibr" rid="bib15">Goker-Alpan, 2011</xref>; <xref ref-type="bibr" rid="bib35">Potnis et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">de Fost et al., 2008</xref>). Therefore, despite multiplicity of proposed mechanisms underlying AVN in GD, the final pathway likely involves the pathogenic lipids, metabolic inflammation, and lipid-laden Gaucher macrophages. These aberrant pathways are expected to be ameliorated by ERTs and eliglustat SRT but their tissue distribution may have a differential effect (<xref ref-type="bibr" rid="bib29">Mistry et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">Weinreb et al., 2021</xref>), for example small molecule SRT vs recombinant MMR-targeted recombinant ERT.</p><p>Our study is the first to critically examine outcomes with respect to types (imiglucerase and velaglucerase) and mode of therapy (eliglustat SRT). In experience garnered over 20 years at a single tertiary referral center involving 1382 cumulative years of GD-specific treatments, we found no episode of AVN among eliglustat SRT-treated patients but there were several episodes among patients receiving imiglucerase and velaglucerase ERT. Unexpectedly, we found compared to imiglucerase ERT, patients receiving velaglucerase ERT had 4.7 odds ratio of AVN (95% CI, 1.67–13.07, p=0.003). The basis for this apparent differential effectiveness to prevent AVN is not known. It should be kept in mind that imiglucerase and velaglucerase are not bioidentical. They differ in glycan residues and have minor amino acid changes. Gene expression analysis in mice infused with these enzymes result in different transcriptional profiles (<xref ref-type="bibr" rid="bib8">Dasgupta et al., 2013</xref>). Moreover, velaglucerase have greater number of mannose residues compared to imiglucerase (<xref ref-type="bibr" rid="bib40">Tekoah, 2013</xref>). Theoretically, greater clearance by the liver and spleen via mannose receptors in macrophages of these organs could result in less delivery to the bone marrow. Additionally, imiglucerase have been shown to reverse osteoblast defect in cell cultures even though osteoblasts do not exhibit mannose receptors (<xref ref-type="bibr" rid="bib34">Panicker et al., 2018</xref>). Our findings underscore the need for investigation of this topic in registry setting such as the Gaucher Outcomes Survey (GOS) that monitor long-term outcomes of velaglucerase ERT (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov:</ext-link> NCT03291223). A phase 4 study on bone outcomes was recently completed, and its results will be relevant (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov:</ext-link> NCT02574286) although the primary end-point for the trial appears to be bone density only. During our study, we did not have any episodes of AVN among patients treated with eliglustat SRT. This is in keeping with strikingly low episodes of AVN in extensive clinical trials (<xref ref-type="bibr" rid="bib7">Cox et al., 2023</xref>). In the ENGAGE placebo-controlled trial, only one episode of AVN occurred in patient on placebo (<xref ref-type="bibr" rid="bib29">Mistry et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cox et al., 2023</xref>).</p><p>Our results advance optimal management of patients with GD based on their biomarker profile. We found that other significant predictors of AVN while receiving treatment included patients with history of AVN prior to initiation of therapy, p.Ser409Asp/other <italic>GBA</italic> genotype and serum GlcSph level. We did not find any association of splenectomy with occurrence of AVN while on treatment. Some studies have suggested association of AVN with splenectomy (<xref ref-type="bibr" rid="bib25">Mistry et al., 2009b</xref>) but studies in longitudinally followed patients in UK showed AVN occurrence frequently preceded splenectomy suggesting that both AVN and need for splenectomy in pre-ERT era were indicators of severe disease (<xref ref-type="bibr" rid="bib9">Deegan et al., 2011</xref>).</p><p>In our cohort, <italic>GBA</italic> genotype had a significant effect on the risk for developing osteonecrosis during treatment. Patients who were heteroallelic for p.Asp409Ser were 10 times more likely than p.Asp409Ser homozygous patients to develop osteonecrosis during treatment. In contrast, p.Asp409Ser/p.Asp409Ser appears to be protective against developing osteonecrosis, underscored by the fact that 51% of our cohort were homozygous for p.Asp409Ser mutation, among whom only one patient developed AVN during treatment. Another significant risk factor for developing AVN on treatment was previous history of AVN prior to treatment initiation.</p><p>The biomarkers of GD, chitotriosidase and GlcSph, are reduced by ERT and eliglustat SRT (<xref ref-type="bibr" rid="bib30">Murugesan et al., 2016</xref>). Of the therapies we examined, we found eliglustat to be most effective in reducing serum GlcSph compared to ERTs (imiglucerase&gt;velaglucerase). We did not find any association of residual chitotriosidase and AVN. This is in keeping with other reports (<xref ref-type="bibr" rid="bib21">Khan et al., 2012</xref>). In our study we found residual serum GlcSph to be significantly associated with risk of AVN. Residual GlcSph level refers to serum concentration measured in sample taken at close proximity to the onset of AVN (but not levels prior to initiation of treatment). For the first time, our data demonstrate the significance of residual biomarker level which should aid patient stratification for risk of AVN among patients receiving treatment. We used a dual cut-off strategy for serum level of GlcSph to stratify patients for the risk of AVN while receiving treatment in GD patients. There were no episodes of AVN when GlcSph level was less than 21.7 ng/ml with a sensitivity of 100% (95% CI, 79.4–100%) and specificity 24.6%. In contrast, GlcSph level of 77.64 ng/ml has sensitivity of 81.2% (95% CI, 54.4–96%) and specificity of 82.8% (95% CI, 80.7–84.8%) for association with AVN in GD patients receiving treatment. Therefore, our findings permit AVN risk stratification based on GlcSph levels into three groups (<xref ref-type="table" rid="table4">Table 4</xref>): patients with low risk: GlcSph&lt;21.7 ng/ml, patients with intermediate risk: 21.8 ng/ml&lt;GlcSph&lt;77.64 ng/ml, and patients at high risk: GlcSph&gt;77.64 ng/ml.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Serum glucosylsphingosine (GlcSph) levels according to probabilities for avascular osteonecrosis (AVN) occurrence while on treatment with dual cut-offs to stratify patients for AVN risk.</title><p>Residual serum GlcSph levels were used to stratify risk of AVN among patients receiving treatment. Our findings permit AVN risk stratification based on GlcSph levels into three groups patients with low risk: GlcSph&lt;21.7 ng/ml, patients with intermediate risk: 21.8ng/ml&lt;GlcSph&lt; 77.64 ng/ml, and patients at high risk: GlcSph&gt;77.64 ng/ml.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">AVN on treatment</th><th align="left" valign="top">GlcSph (ng/ml)</th><th align="left" valign="top">Sensitivity(95% CI)</th><th align="left" valign="top">Specificity(95% CI)</th><th align="left" valign="top">+Likelihood ratio</th></tr></thead><tbody><tr><td align="left" valign="top"> Low risk</td><td align="char" char="." valign="top">&lt;21.7</td><td align="char" char="." valign="top">100<break/>(79.4–100)</td><td align="char" char="." valign="top">24.63<break/>(22.3–27.0)</td><td align="char" char="." valign="top">1.33</td></tr><tr><td align="left" valign="top">Intermediate risk</td><td align="char" char="ndash" valign="top">21.8–77.6</td><td align="char" char="." valign="top">89<break/>(61.3–98)</td><td align="char" char="." valign="top">56.9<break/>(54–62.5)</td><td align="char" char="." valign="top">2.36</td></tr><tr><td align="left" valign="top"> High risk</td><td align="char" char="." valign="top">&gt;77.64</td><td align="char" char="." valign="top">81.25<break/>(54.4–96)</td><td align="char" char="." valign="top">82.78<break/>(80.7–84.8)</td><td align="char" char="." valign="top">4.72</td></tr></tbody></table></table-wrap><p>These findings suggest that it is prudent to aim to achieve GlcSph levels &lt;21.8 ng/ml as a therapeutic goal, that is, &lt;21.8-fold above normal. In practice, the significance of considering these GlcSph levels is greatly enhanced by considering its context of use regarding other risk factors. For example, as shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>, in patients with at least one of delineated risk factors in our study that is compound heterozygosity for p.Asn409Ser, history of AVN prior to treatment or velaglucerase ERT, sensitivity for GlcSph level at 77.64 ng/ml increases to 87.5% (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In patients who harbor at least two of these risk factors, GlcSph level of 77.14 ng/ml has sensitivity of 92.9% and specificity of 78.8% to rule in the probability of AVN on ERT (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In patients with all three risk factors, GlcSph level of 71.8 ng/ml is 100% sensitive to support the probability of AVN with specificity of 82.4% (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>Our findings are not an indication to change ERTs, as we recognize many patients are benefiting from both imiglucerase and velaglucerase. However, our experience suggests that it is unwise for empirical changes in types of ERTs by third parties (<xref ref-type="bibr" rid="bib2">Barranger et al., 2014</xref>). Rather, our findings help to elevate optimal management of GD from prevalent practice of monitoring blood counts with or without biomarkers and occasional imaging to a higher level of risk stratification to identify high-risk patients who would benefit from closer monitoring and treatment optimization. Our study is not without limitations. First, it is a single center study, however, the uniform protocol for comprehensive evaluation and long-term follow-up of individual patients are significant strengths. Second, our center is a tertiary referral center, and a referral bias could have enriched patients with AVN, however, this potential bias would apply across our entire patient population. It will be important to examine the GOS which captures data on outcomes of velaglucerase ERT. Hitherto, reports from GOS have iteratively reported only hematological and visceral outcomes, frequently conflating outcomes from multiple ERTs under a generic term ERT (<xref ref-type="bibr" rid="bib19">Hughes et al., 2022</xref>). It behooves on the investigators to build incremental evidence of efficacy, instead of iterative reports of end-points used in primary trials. It should be noted that in 2014, a study was initiated to assess bone outcomes on velaglucerase ERT (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov:</ext-link> Identifier: NCT02574286), however, there are no reports to date from this study and end-points do not include reduction of AVN incidence.</p><p>In conclusion, our study demonstrates residual risk of AVN on GD patients receiving therapy. Independent risk factors for AVN while patients were receiving therapy were pAsp409Ser/other <italic>GBA</italic> mutation, pre-ERT history of AVN, serum GlcSph level, and velaglucerase ERT. Our results will aid optimal monitoring of GD patients, help enrich clinical trials of rare heterogeneous GD, and stimulate comparative effectiveness analysis in the era of multiple therapies.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Sanofi and may hold stocks</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Validation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Validation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Validation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All participants were enrolled in our observational studies approved by Yale's IRB. Patients also were provided with verbal explanations and their data were collected after signing consent forms. HIC#0209021074HIC#1005006783.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-87537-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STROBE Checklist.</title></caption><media xlink:href="elife-87537-repstand1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>This observational study is approved by Yale University IRB and each patient provided informed consent. The patients have not provided consent to sharing their data with other investigators. Interested academic, non-commercial researchers can contact the Senior Corresponding author, Dr Pramod Mistry at <ext-link ext-link-type="uri" xlink:href="https://medicine.yale.edu/profile/pramod-mistry/">Pramod.mistry@yale.edu</ext-link> to discuss the request to access original data. They do not need to apply or submit a project proposal. All statistical analyses were performed with SPSS version 28 (SPSS Inc, Chicago, IL, USA). MedCalc version 20.026 was used for ROC curve analysis and graphs were plotted by GraphPad Prism version 9.3.1.We do not have consent to share individual patient data. Even de-identified data risks identification through age and GBA genotype information, thus violating HIPPA patient confidentiality. Upon request to the Senior Corresponding author, the PI, we will share processed version of datasets.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank our patients for the opportunity to provide their Gaucher-related care and for their participation in our studies. MB is supported by Lysosomal Disease Fellowship from Sanofi.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreev</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Weidner</surname><given-names>D</given-names></name><name><surname>Kachler</surname><given-names>K</given-names></name><name><surname>Faas</surname><given-names>M</given-names></name><name><surname>Grüneboom</surname><given-names>A</given-names></name><name><surname>Schlötzer-Schrehardt</surname><given-names>U</given-names></name><name><surname>Muñoz</surname><given-names>LE</given-names></name><name><surname>Steffen</surname><given-names>U</given-names></name><name><surname>Grötsch</surname><given-names>B</given-names></name><name><surname>Killy</surname><given-names>B</given-names></name><name><surname>Krönke</surname><given-names>G</given-names></name><name><surname>Luebke</surname><given-names>AM</given-names></name><name><surname>Niemeier</surname><given-names>A</given-names></name><name><surname>Wehrhan</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Bozec</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osteocyte necrosis triggers Osteoclast-mediated bone loss through macrophage-inducible C-type lectin</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>4811</fpage><lpage>4830</lpage><pub-id pub-id-type="doi">10.1172/JCI134214</pub-id><pub-id pub-id-type="pmid">32773408</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barranger</surname><given-names>JA</given-names></name><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Mankin</surname><given-names>H</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Position statement: national Gaucher foundation medical advisory board</article-title><source>American Journal of Hematology</source><volume>89</volume><fpage>457</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/ajh.23687</pub-id><pub-id pub-id-type="pmid">24488939</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boot</surname><given-names>RG</given-names></name><name><surname>Renkema</surname><given-names>GH</given-names></name><name><surname>Verhoek</surname><given-names>M</given-names></name><name><surname>Strijland</surname><given-names>A</given-names></name><name><surname>Bliek</surname><given-names>J</given-names></name><name><surname>de Meulemeester</surname><given-names>TM</given-names></name><name><surname>Mannens</surname><given-names>MM</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The human Chitotriosidase Gene: nature of inherited enzyme deficiency</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>25680</fpage><lpage>25685</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.40.25680</pub-id><pub-id pub-id-type="pmid">9748235</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeau</surname><given-names>PM</given-names></name><name><surname>Rafei</surname><given-names>M</given-names></name><name><surname>Boivin</surname><given-names>MN</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Galipeau</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Characterization of Gaucher disease bone marrow Mesenchymal Stromal cells reveals an altered inflammatory Secretome</article-title><source>Blood</source><volume>114</volume><fpage>3181</fpage><lpage>3190</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-02-205708</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Esplin</surname><given-names>JA</given-names></name><name><surname>Gribble</surname><given-names>TJ</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Scott</surname><given-names>CR</given-names></name><name><surname>Wappner</surname><given-names>RS</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name><name><surname>Wisch</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Gaucher disease: recommendations on diagnosis, evaluation, and monitoring</article-title><source>Archives of Internal Medicine</source><volume>158</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1001/archinte.158.16.1754</pub-id><pub-id pub-id-type="pmid">9738604</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Competing for the treasure in exceptions</article-title><source>American Journal of Hematology</source><volume>88</volume><fpage>163</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/ajh.23399</pub-id><pub-id pub-id-type="pmid">23400870</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>TM</given-names></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Lukina</surname><given-names>E</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Foster</surname><given-names>MC</given-names></name><name><surname>Peterschmitt</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Long-term effects of Eliglustat on Skeletal manifestations in clinical trials of patients with Gaucher disease type 1</article-title><source>Genetics in Medicine</source><volume>25</volume><elocation-id>100329</elocation-id><pub-id pub-id-type="doi">10.1016/j.gim.2022.10.011</pub-id><pub-id pub-id-type="pmid">36469032</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>YH</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Keddache</surname><given-names>M</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Silman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Gaucher disease: Transcriptome analyses using Microarray or mRNA sequencing in a Gba1 mutant mouse model treated with Velaglucerase ALFA or Imiglucerase</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e74912</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0074912</pub-id><pub-id pub-id-type="pmid">24124461</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deegan</surname><given-names>PB</given-names></name><name><surname>Pavlova</surname><given-names>E</given-names></name><name><surname>Tindall</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>PE</given-names></name><name><surname>Bearcroft</surname><given-names>P</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Wraith</surname><given-names>JE</given-names></name><name><surname>Cox</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy</article-title><source>Medicine</source><volume>90</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/MD.0b013e3182057be4</pub-id><pub-id pub-id-type="pmid">21200186</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Fost</surname><given-names>M</given-names></name><name><surname>van Noesel</surname><given-names>CJM</given-names></name><name><surname>Aerts</surname><given-names>JMFG</given-names></name><name><surname>Maas</surname><given-names>M</given-names></name><name><surname>Pöll</surname><given-names>RG</given-names></name><name><surname>Hollak</surname><given-names>CEM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy</article-title><source>Haematologica</source><volume>93</volume><fpage>1119</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.3324/haematol.12651</pub-id><pub-id pub-id-type="pmid">18519519</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekker</surname><given-names>N</given-names></name><name><surname>van Dussen</surname><given-names>L</given-names></name><name><surname>Hollak</surname><given-names>CEM</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><name><surname>Scheij</surname><given-names>S</given-names></name><name><surname>Ghauharali</surname><given-names>K</given-names></name><name><surname>van Breemen</surname><given-names>MJ</given-names></name><name><surname>Ferraz</surname><given-names>MJ</given-names></name><name><surname>Groener</surname><given-names>JEM</given-names></name><name><surname>Maas</surname><given-names>M</given-names></name><name><surname>Wijburg</surname><given-names>FA</given-names></name><name><surname>Speijer</surname><given-names>D</given-names></name><name><surname>Tylki-Szymanska</surname><given-names>A</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Elevated plasma Glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response</article-title><source>Blood</source><volume>118</volume><fpage>e118</fpage><lpage>e127</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-05-352971</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Desnick</surname><given-names>RJ</given-names></name><name><surname>Gatt</surname><given-names>S</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Gaucher Disease, a Century of Delineation and Research</article-title><conf-name>Proceedings of the First International Symposium on Gaucher Disease</conf-name><fpage>22</fpage><lpage>24</lpage></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detry</surname><given-names>MA</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Analyzing repeated measurements using mixed models</article-title><source>JAMA</source><volume>315</volume><fpage>407</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.19394</pub-id><pub-id pub-id-type="pmid">26813213</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drelichman</surname><given-names>GI</given-names></name><name><surname>Fernández Escobar</surname><given-names>N</given-names></name><name><surname>Soberon</surname><given-names>BC</given-names></name><name><surname>Basack</surname><given-names>NF</given-names></name><name><surname>Frabasil</surname><given-names>J</given-names></name><name><surname>Schenone</surname><given-names>AB</given-names></name><name><surname>Aguilar</surname><given-names>G</given-names></name><name><surname>Larroudé</surname><given-names>MS</given-names></name><name><surname>Knight</surname><given-names>JR</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><collab>Argentine Group for Diagnosis and Treatment of Gaucher Disease</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Long-read single molecule real-time (SMRT) sequencing of Gba1 locus in Gaucher disease national cohort from Argentina reveals high frequency of complex allele underlying severe Skeletal phenotypes: collaborative study from the Argentine group for diagnosis and treatment of Gaucher disease</article-title><source>Molecular Genetics and Metabolism Reports</source><volume>29</volume><elocation-id>100820</elocation-id><pub-id pub-id-type="doi">10.1016/j.ymgmr.2021.100820</pub-id><pub-id pub-id-type="pmid">34820281</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goker-Alpan</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Therapeutic approaches to bone pathology in Gaucher disease: past, present and future</article-title><source>Molecular Genetics and Metabolism</source><volume>104</volume><fpage>438</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2011.08.004</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>DE</given-names></name><name><surname>Turkia</surname><given-names>HB</given-names></name><name><surname>Lukina</surname><given-names>EA</given-names></name><name><surname>Kisinovsky</surname><given-names>I</given-names></name><name><surname>Dridi</surname><given-names>M-FB</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Zahrieh</surname><given-names>D</given-names></name><name><surname>Crombez</surname><given-names>E</given-names></name><name><surname>Bhirangi</surname><given-names>K</given-names></name><name><surname>Barton</surname><given-names>NW</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enzyme replacement therapy with Velaglucerase ALFA in Gaucher disease: results from a randomized, Double‐Blind, multinational, phase 3 study</article-title><source>American Journal of Hematology</source><volume>88</volume><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1002/ajh.23381</pub-id><pub-id pub-id-type="pmid">23386328</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Petsko</surname><given-names>GA</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2019">2019</year><chapter-title>Gaucher disease</chapter-title><person-group person-group-type="editor"><name><surname>Valle</surname><given-names>DL</given-names></name><name><surname>Antonarakis</surname><given-names>S</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Mitchell</surname><given-names>GA</given-names></name></person-group><source>The Online Metabolic and Molecular Bases of Inherited Disease</source><publisher-name>McGraw-Hill Education</publisher-name><fpage>1</fpage><lpage>64</lpage></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Mikosch</surname><given-names>P</given-names></name><name><surname>Belmatoug</surname><given-names>N</given-names></name><name><surname>Carubbi</surname><given-names>F</given-names></name><name><surname>Cox</surname><given-names>T</given-names></name><name><surname>Goker-Alpan</surname><given-names>O</given-names></name><name><surname>Kindmark</surname><given-names>A</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Poll</surname><given-names>L</given-names></name><name><surname>Weinreb</surname><given-names>N</given-names></name><name><surname>Deegan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Gaucher disease in bone: from to practice pathophysiology</article-title><source>Journal of Bone and Mineral Research</source><volume>34</volume><fpage>996</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3734</pub-id><pub-id pub-id-type="pmid">31233632</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>DA</given-names></name><name><surname>Deegan</surname><given-names>P</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Göker-Alpan</surname><given-names>Ö</given-names></name><name><surname>Lau</surname><given-names>H</given-names></name><name><surname>Lukina</surname><given-names>E</given-names></name><name><surname>Revel-Vilk</surname><given-names>S</given-names></name><name><surname>Scarpa</surname><given-names>M</given-names></name><name><surname>Botha</surname><given-names>J</given-names></name><name><surname>Gadir</surname><given-names>N</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name><collab>GOS Steering Committee</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Switching between enzyme replacement therapies and substrate reduction therapies in patients with Gaucher disease: data from the Gaucher outcome survey (GOS)</article-title><source>Journal of Clinical Medicine</source><volume>11</volume><elocation-id>5158</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11175158</pub-id><pub-id pub-id-type="pmid">36079085</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Egen</surname><given-names>JG</given-names></name><name><surname>Klauschen</surname><given-names>F</given-names></name><name><surname>Meier-Schellersheim</surname><given-names>M</given-names></name><name><surname>Saeki</surname><given-names>Y</given-names></name><name><surname>Vacher</surname><given-names>J</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sphingosine-1-phosphate Mobilizes Osteoclast precursors and regulates bone homeostasis</article-title><source>Nature</source><volume>458</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nature07713</pub-id><pub-id pub-id-type="pmid">19204730</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Hangartner</surname><given-names>T</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name><name><surname>Taylor</surname><given-names>JS</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Risk factors for fractures and Avascular Osteonecrosis in type 1 Gaucher disease: a study from the International collaborative Gaucher group (ICGG) Gaucher Registry</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>1839</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1680</pub-id><pub-id pub-id-type="pmid">22692814</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Bembi</surname><given-names>B</given-names></name><name><surname>Kanis</surname><given-names>J</given-names></name><name><surname>Reginster</surname><given-names>J-Y</given-names></name><name><surname>Rizzoli</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gaucher disease and bone manifestations</article-title><source>Calcified Tissue International</source><volume>95</volume><fpage>477</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s00223-014-9923-y</pub-id><pub-id pub-id-type="pmid">25377906</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikosch</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An overview on bone manifestations in Gaucher disease</article-title><source>Wiener Medizinische Wochenschrift</source><volume>160</volume><fpage>609</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1007/s10354-010-0841-y</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Deegan</surname><given-names>P</given-names></name><name><surname>Vellodi</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>JA</given-names></name><name><surname>Yeh</surname><given-names>M</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Avascular necrosis in untreated patients with type 1 Gaucher disease</article-title><source>Blood</source><volume>114</volume><elocation-id>1353</elocation-id><pub-id pub-id-type="doi">10.1182/blood.V114.22.1353.1353</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Deegan</surname><given-names>P</given-names></name><name><surname>Vellodi</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>JA</given-names></name><name><surname>Yeh</surname><given-names>M</given-names></name><name><surname>Weinreb</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of Avascular necrosis</article-title><source>British Journal of Haematology</source><volume>147</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07872.x</pub-id><pub-id pub-id-type="pmid">19732054</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Nottoli</surname><given-names>T</given-names></name><name><surname>McGrath</surname><given-names>J</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Keutzer</surname><given-names>J</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Mehal</surname><given-names>WZ</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Mane</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>YZ</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Blair</surname><given-names>HC</given-names></name><name><surname>Robinson</surname><given-names>LJ</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Glucocerebrosidase Gene-deficient mouse Recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage</article-title><source>PNAS</source><volume>107</volume><fpage>19473</fpage><lpage>19478</lpage><pub-id pub-id-type="doi">10.1073/pnas.1003308107</pub-id><pub-id pub-id-type="pmid">20962279</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Belmatoug</surname><given-names>N</given-names></name><name><surname>vom Dahl</surname><given-names>S</given-names></name><name><surname>Giugliani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Understanding the natural history of G Aucher disease</article-title><source>American Journal of Hematology</source><volume>90 Suppl 1</volume><fpage>S6</fpage><lpage>S11</lpage><pub-id pub-id-type="doi">10.1002/ajh.24055</pub-id><pub-id pub-id-type="pmid">26096746</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Batista</surname><given-names>JL</given-names></name><name><surname>Andersson</surname><given-names>HC</given-names></name><name><surname>Balwani</surname><given-names>M</given-names></name><name><surname>Burrow</surname><given-names>TA</given-names></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Kishnani</surname><given-names>PS</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Rosenbloom</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>CR</given-names></name><name><surname>Weinreb</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of Alglucerase/Imiglucerase enzyme replacement therapy in the International collaborative Gaucher group (ICGG) Gaucher Registry</article-title><source>American Journal of Hematology</source><volume>92</volume><fpage>929</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1002/ajh.24801</pub-id><pub-id pub-id-type="pmid">28569047</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Lukina</surname><given-names>E</given-names></name><name><surname>Ben Turkia</surname><given-names>H</given-names></name><name><surname>Shankar</surname><given-names>SP</given-names></name><name><surname>Baris Feldman</surname><given-names>H</given-names></name><name><surname>Ghosn</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Packman</surname><given-names>S</given-names></name><name><surname>Lau</surname><given-names>H</given-names></name><name><surname>Petakov</surname><given-names>M</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><name><surname>Balwani</surname><given-names>M</given-names></name><name><surname>Danda</surname><given-names>S</given-names></name><name><surname>Hadjiev</surname><given-names>E</given-names></name><name><surname>Ortega</surname><given-names>A</given-names></name><name><surname>Foster</surname><given-names>MC</given-names></name><name><surname>Gaemers</surname><given-names>SJM</given-names></name><name><surname>Peterschmitt</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical outcomes after 4.5 years of Eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results</article-title><source>American Journal of Hematology</source><volume>96</volume><fpage>1156</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1002/ajh.26276</pub-id><pub-id pub-id-type="pmid">34161616</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugesan</surname><given-names>V</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lischuk</surname><given-names>A</given-names></name><name><surname>Kacena</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Keutzer</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glucosylsphingosine is a key biomarker of Gaucher disease</article-title><source>American Journal of Hematology</source><volume>91</volume><fpage>1082</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1002/ajh.24491</pub-id><pub-id pub-id-type="pmid">27441734</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation</article-title><source>Blood</source><volume>125</volume><fpage>1256</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-09-600270</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Branagan</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clonal immunoglobulin against Lysolipids in the origin of myeloma</article-title><source>New England Journal of Medicine</source><volume>374</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1508808</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orvisky</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>LaMarca</surname><given-names>ME</given-names></name><name><surname>Ginns</surname><given-names>EI</given-names></name><name><surname>Martin</surname><given-names>BM</given-names></name><name><surname>Tayebi</surname><given-names>N</given-names></name><name><surname>Sidransky</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype</article-title><source>Molecular Genetics and Metabolism</source><volume>76</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/s1096-7192(02)00117-8</pub-id><pub-id pub-id-type="pmid">12208131</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panicker</surname><given-names>LM</given-names></name><name><surname>Srikanth</surname><given-names>MP</given-names></name><name><surname>Castro-Gomes</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Andrews</surname><given-names>NW</given-names></name><name><surname>Feldman</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gaucher disease iPSC-derived Osteoblasts have developmental and lysosomal defects that impair bone matrix deposition</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx442</pub-id><pub-id pub-id-type="pmid">29301038</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potnis</surname><given-names>KC</given-names></name><name><surname>Flueckinger</surname><given-names>LB</given-names></name><name><surname>Ha</surname><given-names>CI</given-names></name><name><surname>Upadia</surname><given-names>J</given-names></name><name><surname>Frush</surname><given-names>DP</given-names></name><name><surname>Kishnani</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bone manifestations in Neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy</article-title><source>Molecular Genetics and Metabolism</source><volume>126</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2018.11.004</pub-id><pub-id pub-id-type="pmid">30448006</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigante</surname><given-names>D</given-names></name><name><surname>Cipolla</surname><given-names>C</given-names></name><name><surname>Basile</surname><given-names>U</given-names></name><name><surname>Gulli</surname><given-names>F</given-names></name><name><surname>Savastano</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Overview of immune abnormalities in lysosomal storage disorders</article-title><source>Immunology Letters</source><volume>188</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2017.07.004</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Chang</surname><given-names>EJ</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Banno</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Sphingosine 1‐Phosphate as a regulator of Osteoclast differentiation and Osteoclast–Osteoblast coupling</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>5840</fpage><lpage>5851</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601430</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saville</surname><given-names>JT</given-names></name><name><surname>McDermott</surname><given-names>BK</given-names></name><name><surname>Chin</surname><given-names>SJ</given-names></name><name><surname>Fletcher</surname><given-names>JM</given-names></name><name><surname>Fuller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Expanding the clinical utility of Glucosylsphingosine for Gaucher disease</article-title><source>Journal of Inherited Metabolic Disease</source><volume>43</volume><fpage>558</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1002/jimd.12192</pub-id><pub-id pub-id-type="pmid">31707742</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonhoven</surname><given-names>A</given-names></name><name><surname>Rudensky</surname><given-names>B</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Hollak</surname><given-names>CEM</given-names></name><name><surname>Groener</surname><given-names>JE</given-names></name><name><surname>Aerts</surname><given-names>JMFG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Monitoring of Gaucher patients with a novel Chitotriosidase assay</article-title><source>Clinica Chimica Acta</source><volume>381</volume><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2007.02.042</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tekoah</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Functionality of Recombinant Β-Glucocerebrosidase from various production systems</article-title><source>Biosci Rep</source><volume>33</volume><elocation-id>e00071</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20130081</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dussen</surname><given-names>L</given-names></name><name><surname>Biegstraaten</surname><given-names>M</given-names></name><name><surname>Dijkgraaf</surname><given-names>MG</given-names></name><name><surname>Hollak</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of Splenectomy and bone complications</article-title><source>Orphanet Journal of Rare Diseases</source><volume>9</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s13023-014-0112-x</pub-id><pub-id pub-id-type="pmid">25056340</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>NJ</given-names></name><name><surname>Camelo</surname><given-names>JS</given-names><suffix>Jr</suffix></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>McClain</surname><given-names>MR</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Belmatoug</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of Imiglucerase treatment</article-title><source>Molecular Genetics and Metabolism</source><volume>132</volume><fpage>100</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2020.12.295</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>M</given-names></name><name><surname>Weinreb</surname><given-names>N</given-names></name><name><surname>Deegan</surname><given-names>P</given-names></name><name><surname>Vellodi</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Avascular necrosis in untreated patients with type 1 Gaucher disease</article-title><conf-name>Molecular Genetics and Metabolism</conf-name></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimran</surname><given-names>A</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Tylki-Szymanska</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>DA</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Mardach</surname><given-names>R</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Heisel-Kurth</surname><given-names>M</given-names></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Harmatz</surname><given-names>P</given-names></name><name><surname>Fernhoff</surname><given-names>P</given-names></name><name><surname>Rhead</surname><given-names>W</given-names></name><name><surname>Longo</surname><given-names>N</given-names></name><name><surname>Giraldo</surname><given-names>P</given-names></name><name><surname>Ruiz</surname><given-names>JA</given-names></name><name><surname>Zahrieh</surname><given-names>D</given-names></name><name><surname>Crombez</surname><given-names>E</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Safety and efficacy of Velaglucerase ALFA in Gaucher disease type 1 patients previously treated with Imiglucerase</article-title><source>American Journal of Hematology</source><volume>88</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1002/ajh.23383</pub-id><pub-id pub-id-type="pmid">23339116</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87537.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.03.21.23287476" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.03.21.23287476"/></front-stub><body><p>This study presents valuable findings on the risk factors of avascular osteonecrosis in patients with Gaucher disease. The evidence supporting the claims of the authors is convincing. The work will interest clinicians who treat patients with inborn errors of metabolism.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87537.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>DaVita Labs</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Yuen</surname><given-names>Tony</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.03.21.23287476">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2023.03.21.23287476v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Osteonecrosis in Gaucher Disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission. There are only a few comments for you to consider.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Overall this manuscript is excellent. In addition to the comments in the public review, the following suggestions are noted for improvement:</p><p>1) While serum GlcSph levels were stratified according to probabilities for AVN occurrence while on treatment, it would be essential to note the longitudinal follow-up of levels for the two patients with multiple AVN episodes. Is there a δ change in the level that would more dramatically increase a patient's risk relative to an overall cutoff level?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.87537.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Overall this manuscript is excellent. The following suggestions are noted for improvement:</p></disp-quote><disp-quote content-type="editor-comment"><p>1) While serum GlcSph levels were stratified according to probabilities for AVN occurrence while on treatment, it would be essential to note the longitudinal follow-up of levels for the two patients with multiple AVN episodes. Is there a δ change in the level that would more dramatically increase a patient's risk relative to an overall cutoff level?</p></disp-quote><p>During 20 years span of this study, we detected 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. Please see Table 2. As shown in Table 2, patient # 7 had developed AVN while the patient was on ERT and the serum level of GlcSph at the time of AVN occurrence was 85 ng/ml. The second episode of AVN occurred a few years later when the serum level of GlcSph was 145.7 ng/ml. Similarly, Patient # 8 developed AVN while the patient was on ERT and the serum level of GlcSph was 61.9 ng/ml. The second episode of AVN occurred a few years later and the serum level of GlcSph was 77.7 ng/ml.</p><p>Therefore at least in these two patients there is a significant δ change in serum GlcSph levels at the time of second AVN episode. While it is not possible to specify overall δ change in serum GlcSph levels as a risk factor for AVN, our study clearly show that serum GlcSph is highly significant risk factor for AVN occurrence.</p></body></sub-article></article>